BRAF V600E in metastatic CRC: encorafenib + cetuximab (with or without binimetinib) impro...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRAF-V600E-CRC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-CRC |
| Sources | SRC-CIVIC SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Actionability Facts
| Biomarker | BIO-BRAF-V600E |
|---|---|
| Variant | V600E |
| Disease | DIS-CRC |
| ESCAT tier | IB |
| Recommended combinations | encorafenib + cetuximab, encorafenib + cetuximab + binimetinib (off-label triplet) |
| Contraindicated monotherapy | vemurafenib alone (CRC-resistant), any BRAFi monotherapy in CRC |
| Evidence summary | BRAF V600E in metastatic CRC: encorafenib + cetuximab (with or without binimetinib) improves OS vs cetuximab+irinotecan in 2L+ (BEACON-CRC, Kopetz et al. 2019). BRAFi monotherapy is ineffective in CRC due to EGFR-mediated feedback reactivation — distinct from melanoma where BRAFi alone works. |
Notes
ESCAT IB per ESMO mCRC living guideline. OncoKB Level 1. Companion diagnostic: any FDA-approved BRAF V600E test (cobas, FoundationOne CDx). Not approved as monotherapy in CRC — combination only. Source ID note: task brief referenced SRC-ESMO-CRC-2024 but the actual KB entity is SRC-ESMO-COLON-2024 (matches the file naming convention for ESMO sources).
Used By
No reverse references found in the YAML corpus.